Accéder directement au contenu Accéder directement à la navigation
Nouvelle interface
Article dans une revue

French Recommendations for Osteoporosis Prevention and Treatment in Patients with Prostate Cancer Treated by Androgen Deprivation

Abstract :

Androgen-deprivation therapy (ADT) in patients with prostate cancer can be achieved surgically or chemically, notably by prescribing LHRH analogs. Major bone loss occurs rapidly in both cases, due to the decrease in testosterone levels, and can increase the fracture risk. The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on a literature review, about osteoporosis prevention and treatment in patients on ADT. The following scientific societies contributed to the work: Société Française de Rhumatologie (SFR), Groupe de Recherche et d’Information sur les Ostéoporoses (GRIO), Groupe Européen d’Etudes des Métastases Osseuses (GEMO), Association Francophone pour les SOins de Support (AFSOS), Association Française d’Urologie (AFU), Société Française de Radiothérapie Oncologique (SFRO). Medication prescription and reimbursement modalities in France were taken into account. The recommendations state that a fracture-risk evaluation and interventions targeting risk factors for fractures should be provided to all patients on ADT. Those patients with a history of severe osteoporotic fracture and/or a T-score <-2.5 should receive osteoporosis therapy. Patients whose T-score is between -1.5 and -2.5 should be treated if they exhibit at least two other risk factors among the following: age ≥75 years, history of nonsevere fracture after 50 years of age, body mass index <19 kg/m², at least three comorbidities (e.g., cardiovascular disease, depression, Parkinson’s disease, and dementia), current glucocorticoid therapy, and repeated falls. When the decision is difficult, FRAX® score determination and an assessment by a bone disease specialist may be helpful. When osteoporosis therapy is not indicated, general measures should be applied, and bone mineral density measured again after 12-24 months. The anti-tumor effects of bisphosphonates and denosumab fall outside the scope of these recommendations.

Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Okina Univ Angers Connectez-vous pour contacter le contributeur
Soumis le : lundi 15 juin 2020 - 21:23:51
Dernière modification le : mardi 22 novembre 2022 - 14:26:15

Lien texte intégral



Karine Briot, Julien Paccou, Philippe Beuzeboc, Jacques Bonneterre, Béatrice Bouvard, et al.. French Recommendations for Osteoporosis Prevention and Treatment in Patients with Prostate Cancer Treated by Androgen Deprivation. Joint Bone Spine, 2019, 86 (1), pp.21-28. ⟨10.1016/j.jbspin.2018.09.017⟩. ⟨hal-02869322⟩



Consultations de la notice